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PNEUMONIA MORTALITY REDUCTIONS OF  
PAST 3 DECADES
Over the last 20–30 years, enormous reductions have occurred 
in the absolute and relative burden of pneumonia mortality in 
young children around the world. Only 20 years ago, when the 
population of young children was approximately 625 million, 
approximately 1.7 million young children died from pneumo-
nia before their 5th birthday (Figure 1) [1–4]. Mortality from 
pneumonia among children aged <5 years fell to 921 000 in 
2015, whereas the population of young children rose to >670 
million [1, 2, 5]. This remarkable improvement in child survival 
and health has resulted from advances in social conditions and 
economic development [6] but has also been influenced by at 
least 4 pivotal innovations: (1) the development of a global vac-
cination program, the World Health Organization’s Expanded 
Program on Immunizations (begun in 1974), which created the 
architecture around which country investments, donor fund-
ing, program strategies, and outcome measurements could be 
envisioned and implemented; (2) the global consensus to focus 
funding, programs, and momentum on 6 development targets 
articulated by the United Nations General Assembly through the 
Millennium Development Goals (MDGs, agreed upon in 2000) 
with MDG4 targeting child survival; (3) the advent of large, 
health-focused nongovernmental organizations; and (4) the 
founding of the Global Alliance for Vaccines and Immunization 
(the Gavi Alliance, formally launched at the World Economic 
Forum in January 2000), a multilateral funding organization 
that has allowed for an unprecedented pace of introduction and 
expanded use of life-saving vaccines in low-income countries. In 
part, as a result of this multidimensional, multisectoral consen-
sus approach enacted through critical large-scale investments 
in prevention, protection, and treatment, pneumonia mortality 
has fallen substantially in many parts of the world because the 
most fatal of the pathogens and the underlying conditions that 
put children at risk are being targeted.
NEW EVIDENCE BASE NEEDED TO REDUCE 
PNEUMONIA BURDEN FURTHER
Over the past 3 decades, much effort has been placed on 
developing, licensing, introducing, and optimizing coverage 
with new vaccines and on developing and implementing evi-
dence-based case management strategies for childhood pneu-
monia. More recently, the focus has extended to reducing the 
underlying conditions that put children at risk of pneumo-
nia mortality, including reducing human immunodeficiency 
virus (HIV) infection through prevention of mother-to-child 
transmission, preventing and treating malnutrition and under-
nutrition, reducing household and outdoor air pollution expo-
sure, and ensuring that prevention and treatment services are 
accessible when and where they are needed. The reduction in 
pneumonia burden over the last decades has not been equal 
S U P P L E M E N T  A R T I C L E
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/cix142
Correspondence: K.  L. O’Brien, International Vaccine Access Center, Johns Hopkins 
Bloomberg School of Public Health, 415 N Washington St, Room 563, Baltimore, MD 21231 
(klobrien@jhu.edu).
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S179/3858224
by London School of Hygiene & Tropical Medicine user
on 29 January 2018
S180 • CID 2017:64 (Suppl 3) • O’Brien et al
across all pathogens, countries, populations, or communi-
ties within countries. Selected pathogens have been targeted 
by vaccines (eg, Haemophilus influenzae type b [Hib], pneu-
mococcus, measles, pertussis), and childhood disease burden 
from these pathogens has therefore been reduced dispropor-
tionately compared with other pathogens. Consequently the 
current etiologic distribution of pneumonia-causing patho-
gens is not just a smaller replica of the etiologic distribution 
from 20–30 years ago. With pneumonia still the leading cause 
of childhood deaths, the importance of quantifying and char-
acterizing the contribution of pathogens causing those deaths 
is key (Figure 1).
Furthur advancing the reduction of pneumonia burden among 
young children means moving beyond the “low-hanging fruit” 
interventions. Innovation is needed not only to maintain the pace 
of pneumonia mortality reduction of the past decade but also to 
accelerate that pace, with the aim of achieving global targets for 
health [7]. With 48% of pneumonia deaths occurring in 5 coun-
tries in Asia and Africa (India, Nigeria, Pakistan, Democratic 
Republic of Congo, and China), which together account for only 
41% of the world’s population aged <5 years [1, 2], an understand-
ing of geographic variability in pneumonia is also important.
Motivated by this global vision for accelerating the pace of 
change, and recognizing that to achieve that vision advances 
would be needed in pneumonia prevention and control, a sim-
ple question was posed to the technical community by the Bill 
& Melinda Gates Foundation several years ago. In a world where 
existing tools to reduce pneumonia mortality have been deployed, 
including the introduction and widespread use of available vac-
cines, what will be the remaining causes of pneumonia and tar-
gets for prevention and treatment? The answer to this question 
will inform investments in tools needed to create an accelerated 
downward inflection in the pneumonia and child mortality rates 
and achieve the goals set by the world for child survival.
ETIOLOGY OF PNEUMONIA MORTALITY IN A NEW 
ERA
An expert consultation on pneumonia, convened by the Bill 
& Melinda Gates Foundation in 2007, recommended that a 
large-scale study of pneumonia etiology be conducted, focus-
ing on severe pneumonia as the closest proxy for pneumonia 
mortality. The Pneumonia Etiology Research for Child Health 
(PERCH) study was commissioned to address this recom-
mendation; its goal is to characterize the etiology of serious 
pneumonia in young children in geographic settings that 
would provide a robust evidence base for strategies to accel-
erate reductions in pneumonia morbidity and mortality, par-
ticularly for children in sub–Saharan Africa and south Asia. 
PERCH enrolled >4000 cases and >5000 controls in 7 coun-
tries (Figure 2) and is likely the most comprehensive study of 
the causes of pneumonia in young children yet undertaken. 
The study has brought together the expertise and advice of 
dozens of investigators from around the world. The epidemi-
ologic basis, strategic decisions, and study methods for the 
PERCH case–control study were published as a supplement 
in 2012 [8].
Figure 1. Annual under-5 all-cause and pneumonia mortality rates with global targets and pivotal health interventions, by time. A, The conceptual pneumonia mortality 
etiology distribution from the preconjugate vaccine era and B, the unknown etiologic distribution of the present and future. Abbreviations: ARVs, antiretrovirals; FDA, US Food 
and Drug Administration; Hib, Haemophilus influenzae type b; MDG, Millenium Development Goal; PCV, pneumococcal conjugate vaccine; SDG, Sustainable Development 
Goal; S. pneumoniae, Streptococcus pneumoniae; WHO, World Health Organization.
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The fundamental and vexing problem in pneumonia etiol-
ogy work is that we cannot usually sample the tissue where 
the disease occurs: the lung. This contrasts sharply with the 
other global public health targets, including diarrhea, measles, 
malaria, and HIV. For pneumonia, we are stuck collecting and 
testing samples from multiple body fluids that are contiguous 
with, but distant from, the site of infection or from body flu-
ids that are a proxy for the site of infection. Pneumonia etiol-
ogy studies require analytic approaches that can integrate data 
from multiple sources through sound epidemiologic and sta-
tistical methods, which produce valid insights into etiology. In 
addition to the challenges of specimen collection, there is also 
imperfect understanding of the likelihood of single-pathogen 
versus multi-pathogen infections in the pathophysiology of 
pneumonia, making the validity of assumptions necessary for 
the analysis of pneumonia etiology data uncertain. Beyond the 
inability to collect specimens from the site of infection, pneu-
monia studies lack a clinical case definition that is both highly 
sensitive and specific, meaning that pneumonia studies will 
either miss substantial groups of children with pneumonia or 
will include substantial numbers of children who do not have 
pneumonia.
This study differs qualitatively and quantitatively from pre-
vious pneumonia etiology studies. The efforts to standardize 
and integrate the clinical, laboratory, epidemiologic, and ana-
lytic approaches and data management have been a cornerstone 
commitment of the project. That is not to say that this study 
is without limitations because no amount of analysis can fully 
overcome the challenges inherent in pneumonia research.
CONTEXT, METHODS, AND PREPARATORY RESULTS 
FROM PERCH
With the articles in this supplement, we begin reporting the 
findings from PERCH. These articles fall into 3 categories: 
context, methods, and preparatory results. We provide results 
from specimens and tests that had not been part of standard 
pneumonia etiology assessments before (eg, polymerase chain 
reaction [PCR] density of detected pathogens in the nasophar-
ynx, induced sputum results, C-reactive protein) to assess their 
inferential value. These articles also aim to provide transpar-
ency on the critical quantitative decisions we have made along 
the path toward the primary etiologic analysis. Several of the 
articles describe efforts to navigate the fundamental problem of 
being unable to sample the lung directly.
Context Articles
These articles offer insights into the pneumonia etiology field 
leading up to the PERCH study and therefore the context 
within which the methods and results should be considered. 
The history of pneumonia etiology article [9] walks through the 
advances and, on occasion, the retreats made in etiology studies 
over the past century. Our reflections and analysis contextualize 
why the PERCH study was designed as it was and the vexing 
limitations that we aimed to overcome through its design. Over 
the past 100 years of pneumonia etiology work, several analytic 
approaches have been used, each with their own benefits and 
limitations, which we organize and interrogate to provide a con-
text for the analytic approaches needed for PERCH [10]. The 
specific issue of determining the appropriate control group for 
Figure 2. Countries where Pneumonia Etiology Research for Child Health (PERCH) study sites are located, and case enrollment numbers. Abbreviations: Emmes, The Emmes 
Corporation; JHSPH, Johns Hopkins Bloomberg School of Public Health.
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the primary analysis was also carefully considered, especially 
the biases that would be introduced with the inclusion or exclu-
sion of control subjects with respiratory symptoms [11].
Methods Descriptions
Next we provide methods articles, which describe the implemen-
tation of the study protocol and analytic approaches that were 
essential for the use of the pneumonia etiology data. PERCH 
was committed to conducting all analyses in a fully standard-
ized way across all 7 countries, using the same protocols, meth-
ods, equipment, and reagents so that etiology differences across 
geographies cannot be explained by heterogeneity in methods. 
Laboratory testing procedures and assessment of the clinical 
data were measured in as standardized a way as possible across 
all sites, which included extensive on-site training and moni-
toring [12, 13]. The chest radiographs formed a key element of 
the case definition for the case–control analysis. Standardized 
reading processes are described, along with their degree of con-
cordance in reading [14]. The lessons and methods used in a 
large, observational, multicountry, multi-investigator study can 
help future studies adopt and further advance best practices, so 
in the data management article we provide a full description of 
the approaches we took to assure the quality of the PERCH data, 
including reductions in misclassifications, errors, and missing 
data [15]. To address the limitations of existing analytic meth-
ods, we developed a new partial latent class, Bayesian analytic 
approach that allows for the integration of microbiologic results 
from multiple body fluids and multiple tests for a single patho-
gen and incorporates adjustments for sensitivity and specificity. 
The model has been described in the statistical computational 
literature [16, 17], and here we provide a description of the 
approach from an epidemiologic perspective [10] and an analy-
sis of the advantages conferred by the new approach [18].
Preparatory Results
Finally we provide articles that report results from PERCH 
cases and controls on issues that are relevant to pneumonia 
etiology studies generally but also inform decisions that were 
needed for the PERCH main etiology analysis. These results are 
not unique to the study settings involved but are generalizable 
and applicable beyond PERCH to other pneumonia diagnostics 
efforts. For example, induced sputum analysis, including for 
tuberculosis [19–23], and pathogen density measurement [24–
26] are 2 strategies that aspired to approximate more closely 
testing for the pathogen infecting the lung. Because blood cul-
ture for bacterial pneumonia detection is poorly sensitive, we 
aimed to understand the impact of pretreatment with antibi-
otics and specimen volume on sensitivity, which is critical for 
analytic adjustments [27]. To increase the sensitivity of these 
bacteremic detections, we assessed the value of whole-blood 
molecular testing on cases and also on controls to quantify the 
limitations of this new diagnostic test in determining etiology 
[28, 29]. In addition, biomarkers like C-reactive protein may 
help distinguish bacterial from nonbacterial causes of pneu-
monia [30]. Chest radiograph findings are critical for char-
acterizing the enrolled cases across the different sites and for 
identifying the cases confirmed to have pneumonia syndrome. 
The results of the chest radiograph reading process designed to 
minimize misclassification and the descriptive findings among 
the cases, by site and case severity, are therefore key to the inter-
pretation of the results from the main etiology analysis [31].
CONCLUSION
The PERCH study has faced a series of critical decisions about 
how to handle numerous data elements, and we have been 
committed to basing those decisions on evidence rather than 
on dogma or anecdote. By clearly showing, through these arti-
cles, the evidence and rationale for the decisions we made, we 
hope to minimize the potential pitfalls of arbitrariness or bias 
in deriving overall etiologic results in our study and for others. 
We also aimed through these preparatory analyses to remove 
the “black box” that can obscure the approach to and analysis 
of complex data.
By publishing these articles on the context, methods, and 
preparatory results from PERCH, we hope to provide the pneu-
monia community a seat at the analytic table. We aim to provide 
transparency in our lines of thinking, in our interrogation of 
the data to inform the decisions necessary for a comprehensive 
analysis of pneumonia etiology, and in our inferences about 
what these data teach us about a complex biologic condition.
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